Methods for successful inactivation of Rift Valley fever virus in infected mosquitoes. by Bergren, Nicholas A et al.
Journal Pre-proof
Methods for successful inactivation of Rift Valley fever virus in infected
mosquitoes
Nicholas A. Bergren (Conceptualization)<ce:contributor-role>Data
Curation)<ce:contributor-role>Formal Analysis) (Investigation)
(Methodology)<ce:contributor-role>Project Administration)
(Resources) (Validation) (Visualization) (Writing - original draft)
(Writing - review and editing), Edward I. Patterson
(Conceptualization), Heather Blair (Writing - review and editing),
Robert P. Ellis (Writing - review and editing), Rebekah C. Kading
(Conceptualization)<ce:contributor-role>Funding Acquisition)
(Resources) (Supervision) (Writing - review and editing)
PII: S0166-0934(19)30383-0
DOI: https://doi.org/10.1016/j.jviromet.2019.113794
Reference: VIRMET 113794
To appear in: Journal of Virological Methods
Received Date: 21 August 2019
Revised Date: 26 November 2019
Accepted Date: 30 November 2019
Please cite this article as: Bergren NA, Patterson EI, Blair H, Ellis RP, Kading RC, Methods for
successful inactivation of Rift Valley fever virus in infected mosquitoes, Journal of Virological
Methods (2019), doi: https://doi.org/10.1016/j.jviromet.2019.113794
This is a PDF ﬁle of an article that has undergone enhancements after acceptance, such as
the addition of a cover page and metadata, and formatting for readability, but it is not yet the
deﬁnitive version of record. This version will undergo additional copyediting, typesetting and
review before it is published in its ﬁnal form, but we are providing this version to give early
visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal
pertain.
© 2019 Published by Elsevier.
1 
 
Methods for successful inactivation of Rift Valley fever virus in infected mosquitoes 
 
Nicholas A. Bergren1, Edward I. Patterson2, Heather Blair3, Robert P. Ellis3, and Rebekah C. 
Kading1 
1 Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and 
Biomedical Science, Colorado State University. 
2 Department of Vector Biology, Liverpool School of Tropical Medicine 
3 Biosafety Office, Colorado State University 
 
Keywords: select agent, paraformaldehyde, trizol, surrogate virus, guanidinium thiocyanate 
 
Summary: Ensuring the successful inactivation of select agent material is critical for maintaining 
compliance with federal regulations and safeguarding laboratory personnel from exposure to 
dangerous pathogens. Rift Valley fever virus (RVFV), naturally transmitted by mosquitoes, is 
classified as a select agent by the CDC and USDA due to its potential to cause significant 
economic losses to the livestock industry and its demonstrated potential to emerge into naïve 
geographic areas. Herein we describe several effective inactivation procedures for RVFV 
infected mosquito samples. We also demonstrate the vaccine strain MP-12 can be used as an 
appropriate analog for inactivation testing and describe a method of validating inactivation using 
Amicon filters. Briefly, we show the following inactivation methods are all effective at 
inactivating RVFV and MP-12 by following the manufacturers’/established protocols: 4% 
paraformaldehyde, Trizol LS (ThermoFisher Scientific), MagMAX™-96 Viral RNA Isolation 
Kit (ThermoFisher Scientific), and Mag-Bind® Viral DNA/RNA 96 Kit (Omega Bio-Tek). 
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Rift Valley fever virus (RVFV) (order: Bunyavirales, family: Phenuiviridae, genus: 
Phlebovirus) is an enveloped, single-stranded, negative sense RNA virus with a tripartite genome 
(Bouloy and Weber, 2010). The virus is mosquito-transmitted, causes severe epidemics among 
ruminants and humans, and is endemic to eastern and southern Africa (Daubney, Hudson, and 
Garnham, 1931; Linthicum, Britch, and Anyamba, 2016; Weaver and Reisen, 2010). RVFV has 
also demonstrated an ability to emerge into non-endemic areas due to the wide disbursement of 
vectors capable of transmitting the virus; this is highlighted by the recent introduction of RVFV 
to the Arabian Peninsula (Al-Afaleq and Hussein, 2011), a recent outbreak on Mayotte island 
(Touze, 2019), and other introductions to islands located in the Indian Ocean (Balenghien et al., 
2013). Furthermore, importation of infectious mosquito vectors and viremic travelers present a 
realistic threat for virus introduction into North America (Golnar, Kading, and Hamer, 2018; 
Konrad and Miller, 2012). Because of the potential for RVFV to cause severe disease in both 
human and domestic animal species, its ability to emerge into naïve geographic locations, its 
history as a bioterrorism agent (Borio et al., 2002), and its potential to cause significant 
economic losses to the livestock industry,  the Centers for Disease Control and Prevention 
(CDC) and United States Department of Agriculture (USDA) have classified RVFV as an 
overlap select agent (Federal Select Agents Program, 2018). The term “select agent” refers to a 
group of biological agents for which the United States has deemed to have the potential to pose a 
severe threat to public health and safety. 
Several gaps exist in our current understanding of RVFV including its disease mechanisms, 
ecology, and epidemiology (Bird and McElroy, 2016). Understanding how human genetic factors 
contribute to disease outcome; why human maternal-to-fetal transmission is so rare when 
ungulate maternal to fetal transmission is so prevalent; the underlying factors of RVFV induced 
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retinitis and encephalitis; and how the virus is maintained during inter-epidemic periods are all 
not well understood. Notably, many mosquito vectors are competent for horizontally transmitting 
RVFV in the laboratory, but more work must be completed to understand the risk of RVFV 
establishment and transmission in different geographic areas (Brustolin et al., 2017; Turell et al., 
2013a; Turell, Byrd, and Harrison, 2013b; Turell, Wilson, and Bennett, 2010). Another critical 
aspect of RVFV transmission in East Africa is the transovarial transmission (TOT) of the virus 
from adult female Aedes (Neomelaniconion) macintoshi mosquitoes to their offspring 
(Linthicum, Davies, and Kairo, 1985). TOT is a common phenomenon among the Bunyavirales 
(Bergren and Kading, 2018), and the potential contribution of this transmission mechanism to 
RVFV establishment in North American mosquito vectors has not yet been adequately assessed.  
Modeling efforts to estimate the establishment potential of RVFV in North America have either 
assumed exceptionally low TOT rates due to the lack of experimental data (Barker et al. 2013), 
or not incorporated this parameter at all (Golnar et al., 2014).  
In order to effectively mitigate virus transmission in the field, experimental studies with 
virulent RVFV must be conducted in a containment laboratory to understand the particular 
vectors to target and vulnerabilities in transmission that can be blocked. Furthermore, laboratory 
studies can generate data to parameterize risk models and more accurately assess the potential for 
RVFV establishment in regions such as the United States. Many laboratory studies have 
contributed to our understanding of virus transmission with other arboviruses and can focus on 
various aspects of arbovirus transmission including assessing the competency of different strains 
of virus (Weger-Lucarelli et al., 2016) and local vectors (Gendernalik et al., 2017), comparing 
the transmission of different mosquito species (Hurk et al., 2010) and different populations 
within the same species (Bennett et al., 2002), assessment of transmission dynamics under 
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different experimental/environmental conditions (Muturi, Blackshear Jr., and Montgomery, 
2012), exploration of mechanisms that drive transmission efficiency for the vector (Bennett et 
al., 2005) and virus (Tsetsarkin et al., 2007), and evaluation of transmission blocking strategies 
(Magalhaes et al., 2019). 
Downstream analysis of inactivated samples is often required to accomplish the studies 
outlined above. These analyses include various molecular and immunological techniques such as 
RT-qPCR, Sanger and next-generation sequencing, and immunofluorescence assay. Efficient and 
effective inactivation of infectious biological material is critical for the safety of laboratorians 
and their communities particularly when working with select agents.   
In 2017, stringent regulations went into effect to address gaps that were discovered regarding 
inactivation of infectious biological material, specifically biological select agents.  The Division 
of Select Agents and Toxins (DSAT) mandated that all inactivation procedures be validated in-
house and approved by each institution’s Select Agent Responsible Official. Further, verification 
of complete inactivation is required upon each occasion an inactivation method is used and 
inactivated select agent material is removed from select agent registered space. Guidelines for 
the inactivation of select agents from the CDC and the USDA- Animal and Plant Health 
Inspection Services allow for the use of a surrogate virus to validate inactivation procedures so 
long as the virus has the same or greater resistance to the inactivation procedure (7 CFR Part 
331, 9 CFR Part 121.3, 42 CFR Part 73.3, CDC and USDA, 2017). Compliance with the above 
regulations becomes complicated when studying RVFV in mosquitoes as these experiments 
usually require biosafety level 3 (BSL3) and arthropod containment level 3 (ACL3) facilities, 
large sample sizes, and high throughput methodologies to process the samples.  
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In order to facilitate compliance with federal select agent regulations when conducting 
critical transmission experiments involving this high consequence emerging virus, we present 
several methods of inactivating mosquito samples infected with an epidemic strain of RVFV as 
well as the vaccine stain MP-12. MP-12 is a live attenuated vaccine of RVFV generated by 
passing the ZH548 strain 12 times in MRC-5 cells in the presence of 5-fluorouracil (Caplen, 
Peters, and Bishop, 1985). Specifically, we show the effectiveness of Trizol LS™ (Thermo 
Fisher Scientific), MagMAX™ Viral RNA Isolation Kit (Thermo Fisher Scientific), Mag-Bind® 
Viral DNA/RNA 96 Kit (Omega Bio-Tek), and 4% paraformaldehyde fixation at inactivating 
infectious RVFV particles and an avirulent surrogate, MP-12. MagMAX™ and Mag-Bind® are 
both magnetic bead-based RNA extraction methods that allow for high throughput of samples 
(an attribute that is extremely valuable when conducting vector competence studies). 
Furthermore, these bead-based systems allow for automation which further increases throughput. 
We also chose to test Trizol LS™ as it is commonly used and has been well documented to 
efficiently inactivate samples (Blow et al., 2004; Patterson et al., 2018). Four percent 
paraformaldehyde fixation was chosen because of a well-established methodology for its 
utilization to visualize RVFV antigen in infected mosquitoes (Kading, Crabtree, and Miller, 
2013). These methods will be beneficial to the research community in providing methods of 
inactivation and validation that can be used in-house.   
To test the effectiveness of virus inactivation by lysis buffers commonly used for nucleic acid 
isolation, which is a common requirement in vector competence experiments, we inoculated 
Culex tarsalis mosquitoes via the intrathoracic (IT) route as described previously (Rosen and 
Gubler, 1974). Mosquitoes were injected with 138nL of an epidemic strain of RVFV 
(Kenya128B-15) at a titer of 1.09x107 plaque forming units (PFU)/mL (approximately 1,500 
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PFU inoculated) or the MP-12 vaccine strain at a titer of 2.16x107 PFU/mL (approximately 2,980 
PFU MP-12 inoculated), using a Nanoject III (Drummond Scientific). A total of 60 mosquitoes 
were required for the subsequent analyses for each virus (120 total), thus we injected 70 
mosquitoes per virus to allow for attrition. Mosquitoes were held at 26ºC with 75% relative 
humidity and a 16:8h light:dark cycle for one week. Mosquitoes were also provided water and 
sugar ad libitum. After one week, mosquitoes were collected (1 per tube) into 2mL gasketed 
tubes (Sarstedt) containing two 5mm glass beads (Millipore) and 250µL mosquito diluent. 
Mosquito diluent consisted of Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) 
supplemented with 20% fetal bovine serum (FBS) (Atlas Biologicals), 50 U/mL Penicillin-
Streptomycin (P-S) (Gibco), 0.05 mg/mL gentamycin (Sigma), and 0.5 mg/mL Amphotericin B 
(Gibco). Mosquitoes were stored at -80ºC prior to inactivation method assessment. A graphical 
flowchart of the experimental design is provided in Figure 1. 
 To ensure mosquitoes were uniformly infected with wild-type RVFV or MP-12, plaque 
assays were conducted on a subset of ten mosquitoes, of the total 120 (%), for each virus. 
Mosquitoes were homogenized in a MagNA Lyser (Roche) at 6,000 rotations per minute (rpm) 
for 30 seconds. Mosquito homogenate was then clarified via centrifugation at 12,000xg for 2 
minutes in a MiniSpin centrifuge (Eppendorf). Plaque assays were conducted on Vero cells as 
previously described and allowed to incubate for 72 hours prior to fixation (Beaty, Calisher, and 
Shope, 1995). After the seven-day incubation, we found every mosquito was infected with mean 
titers 3.44x105 and 1.63x105 PFU/mosquito for RVFV/Kenya128B-15 and RVFV/MP-12, 
respectively (Figure 2).  
 To assess the effectiveness of Trizol LS™, the MagMAX™ Viral RNA Isolation Kit, and 
the Mag-Bind® Viral DNA/RNA 96 Kit, mosquito samples were homogenized and clarified as 
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described above (20 mosquitoes per extraction method). For reference, previous studies 
exploring the inactivation of RVFV-infected mosquitoes utilized three mosquitoes per group 
over various time points (Kading et al., 2013). Inactivation protocols were then followed for each 
reagent as per manufacturer’s instructions. For Trizol LS™, 200µL of clarified homogenate was 
added to 750µL Trizol LS™ reagent followed by mixing via vortex for 30 seconds. For 
MagMAX™, the Lysis/Binding Solution was prepared as instructed by adding 63µL 100% 
isopropanol (Sigma) to 77µL Lysis Binding Solution Concentrate for a total of 140µL. Thirty 
microliters of clarified mosquito homogenate was then applied to 140µL Lysis/Binding Solution, 
samples were then mixed by pipetting. For Mag-Bind®, lysis mastermix was prepared as 
instructed by adding 70µL 100% isopropanol to 60µL TNA Lysis Buffer for a total of 130µL. 
Fifty microliters of clarified mosquito homogenate was then applied to 130µL lysis mastermix, 
samples were then mixed by pipetting. Time to inactivation is not listed on any of the protocols 
tested. To account for this we kept all samples at room temperature for five minutes prior to 
testing for inactivation.   
 MagMAX™, Mag-Bind®, and Trizol LS™ all utilize guanidinium thiocyanate, a 
chaotrope, to inactivate samples by solubilizing lipid bilayers and denaturing proteins. Because 
applying inactivation media directly to cells would result in cell death, samples were washed 
twice with 15mL DPBS (Gibco) in centrifugal concentrators (Amicon Ultra, MWCO: 10kDa; 
Millipore) at 4,000xg for 20 minutes. A final wash of 15mL DMEM supplemented with 2% FBS 
and 50 U/mL P-S was conducted so that the resulting ~200µL could be directly transferred to 
Vero cell monolayers on 12-well plates. Plates were incubated as described above for one hour, 
followed by adding 1mL of DMEM with 2% FBS and 50 U/mL P-S and incubating for a further 
three days. After incubation, plates were inspected for cytopathic effect (CPE) and recorded. 
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Regardless of if CPE was found 200µL was passaged onto new Vero cell monolayers on 12-well 
plates and processed exactly as the first passage. Mosquitoes that had not been subjected to an 
inactivation method were used as positive controls to provide validation of inactivation and use 
of centrifugal concentrators. These positive control mosquitoes were processed identically to the 
experimental samples (filtration and subsequent washing through centrifugal concentrators, etc.) 
to ensure comparability. Additionally, an uninfected well was included for all CPE assays for 
comparison to positive control and experimental wells and to control for potential contamination.  
All control mosquitoes showed CPE for first and second passages; Trizol LS™, MagMAX™, 
and Mag-Bind® protocols all consistently inactivated RVFV derived from infected mosquitoes, 
both virulent and vaccine strains (Figure 3). Mosquito infections were conducted under 
institutional biosafety approved protocol 16-078B. 
To assess the effectiveness of 4% paraformaldehyde at inactivating both RVFV strains we 
IT-injected the infected mosquitoes, described above, with 276nL 4% paraformaldehyde (12% 
paraformaldehyde diluted in DI water, Electron Microscopy Sciences) (20 mosquitoes for each 
virus) in order to perfuse them with the fixative (Kading et al., 2013). Following injection, legs 
and wings were removed and discarded, mosquitoes were briefly submerged in 70% ethanol to 
break their hydrophobicity, and submerged in 1mL 4% paraformaldehyde for 24 hours. After 24 
hours mosquitoes were transferred to 70% ethanol for another 24 hours. Samples were held at 
room temperature for all parts of this protocol. Mosquitoes were then transferred to 
homogenization tubes with mosquito diluent and two glass beads. Mosquitoes were processed as 
described above. Because of the residual paraformaldehyde in the sample, 200µL of the resulting 
clarified mosquito homogenate was applied to the centrifugal concentration and passage protocol 
Jo
urn
al 
Pre
-pr
oo
f
10 
 
as described above. All samples showed complete inactivation of infectious virus particles on 
both passages (Figure 3). 
All four methods successfully inactivated both wild-type RVFV and the MP-12 vaccine 
strain. The inactivation methods explored in this study represent the most relevant methods for 
inactivating virus derived from infected mosquito tissues due to their ability to be used in a high 
throughput manner and the downstream relevance in laboratories studying mosquito-virus 
interactions. We have also shown that MP-12 is an appropriate surrogate strain with which to 
validate inactivation procedures before these procedures are used with wild-type RVFV, as the 
analysis conducted will satisfy the select agent requirements in that this potential surrogate strain 
“possesses equivalent properties as the wild-type strain with respect to inactivation” (7 CFR Part 
331, 9 CFR Part 121.3, 42 CFR Part 73.3) (Figure 2).  While only one biological replicate was 
conducted, the inactivation methods tested were conducted under rigorous conditions and 
manufacturer’s protocols and storage recommendations were followed exactly. The select agent 
inactivation regulations require that the inactivation procedures be validated “using a viability 
testing protocol” (7 CFR Part 331, 9 CFR Part 121.3, 42 CFR Part 73.3), for which we selected 
assessment of CPE on cell monolayers. Given the rapid replication of RVFV and inclusion of 
positive and uninfected controls for visual comparison, assessing CPE three days post infection 
provided appropriate sensitivity to determine whether or not infectious virus was present. 
Alternatively, plaque assays could also have been performed as an appropriate viability 
assessment method. While each individual lab will have to validate these protocols in-house, our 
goal was for this study to provide a framework to efficiently choose and validate the methods 
best fit for their specific research aims. 
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Figure 1. Graphical flowchart of experimental design with sample numbers. A) Culex tarsalis IT 
inoculated with RVFV/Kenya128B-15 or RVFV/MP-12, n=70 per virus (extra 10 to allow for 
attrition). B) 1 week incubation: 26°C, 75% relative humidity, 16:8 light dark cycle, C1) harvest 
infected mosquitoes in 2ml screwcap tubes with 250μl diluent and two 5mm glass beads, n=50 
per virus. C2) 4% paraformaldehyde IT inoculated, dipped in 70% EtOH, legs & wings removed, 
submerged in 4% paraformaldehyde for 24 hours, transferred to 70% EtOH 24 hours, transfer to 
storage tubes with diluent, n=10 per virus. D) Samples for plaque assay, n=10 per group. E1) 
CPE positive controls, n=10 per group. E2) Run inactivation assays: Trizol LS, MagMAX-96, 
Mag-Bind, n=10 per group. F) Run samples through Amicon filter protocol, followed by CPE 
assay (2 passages), n=10 per group. 
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Figure 2. Titers of RVFV in individual positive control mosquitoes (not inactivated) for each 
virus tested (n=10 mosquitoes per virus) after IT injection, seven-day incubation, and collection. 
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Figure 3. The percent of wells with visible CPE for each inactivation method for 
RVFV/Kenya128B-15 and RVFV/MP-12 (data represents one biological replicate). Every well 
was observed for CPE, the percentage reflects the amount of CPE present in the well as 
determined by the investigator. 
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